# Beyond Air (XAIR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/XAIR
## Company Profile
- Ticker: XAIR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: MedTech, Respiratory
## Stock Data
- Close: 5.69 USD
- Market cap: 5965561.4799999995 USD
- Last updated: 2026-08-05
## Business Overview
### Nitric Oxide Medical Technology Platform
Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide-based products for respiratory disease, neurological conditions, and solid tumors. Its first product, LungFit PH, is FDA-approved and CE-marked for hypoxic respiratory failure in term and near-term newborns.
### Cylinder-Free LungFit System
LungFit is a phasic-flow nitric oxide generation and delivery system that produces nitric oxide from ambient air without high-pressure cylinders. The design reduces cylinder inventory, storage requirements, and nitrogen dioxide venting while simplifying hospital operations.
### Commercial and International Reach
Beyond Air is commercializing LungFit PH in the United States and through a distribution network covering more than 45 countries. Regional partners provide regulatory and market access beyond the company’s direct U.S. organization.
### Second-Generation Product Strategy
The second-generation LungFit PH is designed to be smaller, lighter, easier to operate, and suitable for a broader range of care settings. The updated system is also intended to support patient transport use.
### Nitric Oxide Platform Beyond Respiratory Care
Beyond Air is also exploring nitric oxide biology in neurological disease and solid tumors. These programs extend the company’s technology base beyond hospital respiratory delivery, although LungFit PH remains its commercial foundation.
## Why The Stock Is Moving

As of Aug 5, 2026, XAIR closed down 7.93% at $5.69. No new same-company headline was identified in the current news window.

## Future Catalysts

- An FDA decision is pending on the PMA supplement for the second-generation LungFit PH system.
- The PMA supplement also seeks an expanded label covering use during air and ground patient transport.
- Regional regulatory submissions for LungFit PH continue through local partners, with future approvals determining the scope of international commercialization.

## Recent News
- 2026-08-04 12:00 EST — [Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026](https://biopharmsignal.com/news/XAIR/beyond-air-schedules-conference-call-to-discuss-financial-results-for-the-quarte-a4714eb0) — Source: Beyond Air
- 2026-07-30 11:00 EST — [Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/XAIR/beyond-air-announces-up-to-30-1-million-private-placement-offering-priced-at-the-9860617a) — Source: Beyond Air
- 2026-06-26 11:00 EST — [Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XAIR/beyond-air-reports-fourth-quarter-and-full-year-2026-financial-results-and-provi-8c4a9c6f) — Source: Beyond Air
- 2026-06-22 20:01 EST — [Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast](https://biopharmsignal.com/news/XAIR/beyond-air-schedules-fiscal-year-end-2026-financial-results-conference-call-and--03178c17) — Source: Beyond Air
- 2026-06-10 12:00 EST — [Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting](https://biopharmsignal.com/news/XAIR/beyond-air-inc-urges-stockholders-to-vote-for-all-proposals-ahead-of-the-upcomin-31020f6e) — Source: Beyond Air